Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?

dc.date.accessioned	2020-10-21T06:45:51Z
dc.date.available	2020-10-21T06:45:51Z
dc.date.issued	2019
dc.date.issued	2018/10/31
dc.identifier.citation	Hacıoğlu MB, Sakin A, Demir T.Cancer Chemother Pharmacol. 2019 Jan;83(1):115-122. doi: 10.1007/s00280-018-3713-6. Epub 2018 Oct 29.
dc.identifier.uri	http://doi.org/10.1007/s00280-018-3713-6
dc.identifier.uri	https://hdl.handle.net/20.500.12619/71720
dc.description	PMID = 30374523
dc.relation.isversionof	10.1007/s00280-018-3713-6
dc.rights	info:eu-repo/semantics/closedAccess
dc.title	Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?
dc.type	article
dc.relation.journal	Cancer Chemother Pharmacol
dc.identifier.doi	10.1007/s00280-018-3713-6
dc.contributor.author	Köstek O
dc.contributor.author	Hacıoğlu MB
dc.contributor.author	Sakin A
dc.contributor.author	Demir T
dc.contributor.author	Sarı M
dc.contributor.author	Ozkul O
dc.contributor.author	Araz M
dc.contributor.author	Doğan AF
dc.contributor.author	Demircan NC
dc.contributor.author	Uzunoğlu S
dc.contributor.author	Çiçin İ
dc.contributor.author	Erdoğan B.
dc.relation.publicationcategory	Makale - Uluslararası Hakemli Dergi